STOCKS TELEGRAPH

Tag: RCKT Stock

  • Rocket Pharmaceuticals (NASDAQ: RCKT) rocketed in the after-hours after this hot information.

    Rocket Pharmaceuticals (NASDAQ: RCKT) rocketed in the after-hours after this hot information.

    In the After-hours session last night, Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) surged 33.16% to $42.65 after a report of phase 1 clinical trial of RP-A501, the Company’s adeno-associated viral vector (AAV)-based gene therapy candidate expressing LAMP2B for the treatment of Danon Disease, today announces early results from its open-label, Phase 1 clinical trial of RP-A501.

    Danon Disease is a rare inherited X-linked condition caused by genetic defects in the LAMP2 gene contributing to autophagosomal and glycogen accumulation, especially in the cardiac muscle and other tissues, leading eventually to severe and often fatal cardiomyopathy. Preliminary results from low dose RP-A501 cohort patients indicated that gene therapy was relatively well-received, and early evidence of clinical benefit was given.

  • Rocket Pharmaceuticals (RCKT) Announces Third Quarter Financial Results

    Shares of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) soared 10.93% after the company announced today the 2020 financial results of the Third quarter ended September 30, 2020. The company has also disclosed the update of its business operations, upcoming milestones, and key developments.

    It has reported the Cash, cash equivalents, and investments as of September 30, 2020, of $228.7 million. Its balance sheet includes $52.0 million of fully convertible notes. Rocket Pharmaceuticals has reported that its Research & Development expenses for the three months ended September 30, 2020, were $21.7 million.

    The biotechnology company has revealed that it has recorded the General and administrative expenses of $5.7 million for the three months ended September 30, 2020.  Its Net loss was $29.0 million or $0.53 per share for the three months ended September 30, 2020. Furthermore, it has reported the 55,204,127 shares of common stock were outstanding as of September 30, 2020.

    Rocket Pharmaceuticals revealed that the Phase 1/2 clinical trial of RP-L201 for LAD-I has shown positive results.  It has announced that the first patient has received a higher dose level of 1.1×1014 genome copies/kilograms after clearance from the U.S.

    Furthermore, it has announced the establishment of the Research & Development (R&D) and Chemistry, Manufacturing, and Controls (CMC) facility in Cranbury, New Jersey. The new facility is 103,720 square feet. It has dislcosed that the Fast Track Designation has been granted to RP-L401 gene therapy for IMO and RP-A501 for Danon Disease got Rare Pediatric Disease Designation.

    Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) shares were trading up 9.39% at $32.14 at the time of writing on Wednesday. It has a trading volume of 201.27K as compared to the average volume of 273.50K. Rocket Pharmaceuticals, Inc. (RCKT) share price went from a low point around $9.01 to briefly over $30.43 in the past 52 weeks. RCKT market cap has remained high, hitting $1.67 Billion at the time of writing.